Dr Reddy's Laboratories Stock News

BSE benchmark Sensex plummeted 778 points to close below the 55,500-level on Wednesday following a broad-based selloff in global markets as the Russia-Ukraine crisis escalated. The 30-share BSE index ended 778.38 points or 1.38 per cent lower at 55,468.90. Similarly, the NSE Nifty plunged 187.95 points or 1.12 per cent to 16,605.95. Maruti was the top loser in the Sensex pack, shedding 6 per cent, followed by Dr Reddy''s, Asian Paints, ICICI Bank, HDFC and HDFC Bank.

Maruti was the top loser in the Sensex pack, shedding 6 per cent, followed by Dr Reddy''s, Asian Paints, ICICI Bank, HDFC and HDFC Bank.

Brokerage Radar: Jefferies has upgraded its rating on shares of Biocon to ''buy'' while CLSA believes geopolitical tensions might add to supply chain challenges in the short term for automakers. Here are top brokerage calls for this morning:

As many as 77 stocks from BSE 500 index which hit their 52-week low in the morning session on Thursday, include Dr Reddy''s, Exide Industries, HDFC Life, Apollo Tyres, BPCL, DCB Bank, HDFC Asset Management Company Ltd, Gillette India Ltd, and Wockhardt Ltd.

CLSA sees a favourable risk-to-reward ratio in shares of Dr Reddy''s Laboratories, Cadila Healthcare and Torrent Pharma. The brokerage has upgraded Torrent Pharma to ''buy'' from ''outperform'' with an unchanged target price of ₹3,550.

Indian equity benchmark indices opened gap-down on Tuesday tracking weak global markets amid rising Russia-Ukraine tensions. All the 30 Sensex constituents were in the negative territory. Losses were led by Dr Reddy''s, Asian Paints, TCS, L&T, IndusInd Bank, HDFC twins, Bajaj Finserv, whose stock were down 2-3 percent.

Sensex plunges 1,000 pts, Nifty below 16,900, breaches 200-DMA; Smallcap index slides 2%; India VIX surges 16%; L&T, Dr Reddy''s Labs drop 3% each.

As many as five top 100 companies have reported over 150 per cent surge in net profit for the December quarter, with Dr Reddy''s Labs leading the chart with a 54 times jump (5,297 per cent) in bottom line on a year-on-year basis. All these stocks are a ''buy'' with an upside target of 19-25 per cent, suggest consensus estimates. Stock Ideas

The acquisition of the product is expected to strengthen the company’s presence in the inhalation respiratory market segment, Mankind Pharma said.

Mankind Pharma on Wednesday said it has inked a pact with Dr Reddy''s Laboratories to acquire two brands -- Combihale and Daffy. While Combihale is used for the treatment of asthma and chronic obstructive pulmonary disease, Daffy is a soap-free moisturising

Mankind Pharma on Wednesday said it has inked a pact with Dr Reddy''s Laboratories to acquire two brands -- Combihale and Daffy. While Combihale is used for the treatment of asthma and chronic obstructive pulmonary disease, Daffy is a soap-free moisturising bar for infants. Mankind Pharma said the market for Combihale is valued at Rs 900 crore growing at 14 per cent.

Dr. Reddy’s will have exclusive rights to promote and distribute the well-established Voveran range, the Calcium range and Methergine in India.

Dr Reddy''S Laboratories has entered into an exclusive sales and distribution agreement with Novartis India (NIL) for the Voveran range, the calcium range and Methergine in India.

Novartis India has signed an exclusive sales and distribution pact with Dr Reddys Laboratories for a few of its medicines

Dr Reddy''s Laboratories has entered into an exclusive sales and distribution agreement with Novartis India Ltd (NIL), a statement said on Friday. However, this will also lead to around 400 NIL employees being laid off due to role redundancies. Under the arrangement, Dr Reddy''s will have exclusive rights to promote and distribute the well-established Voveran range, the Calcium range and Methergine in India. The company will use its strengths in promotion and distribution to considerably expand its engagement with healthcare professionals with the aim of enabling access to patients in need. "We are delighted to enter into this arrangement with NIL to promote and distribute these well-established brands that are trusted by patients and healthcare professionals," Dr Reddy''s Laboratories CEO - Branded Markets (India and Emerging Markets) M V Ramana said in the statement. The company''s India business has been a strong growth driver and remains a key focus market for the drugmaker, he added.